Bobak R. Azamian is CEO & Chairman +1 at Tarsus Pharmaceuticals, Inc. (TARS). They have made 26 open-market trades across 1 company since 2021, most recently 2026-09-04.
CIK 0001827672
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 26 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 827,991 | $56.4M |
Shares reported on the most recent Form 4, priced at the 2026-09-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | SELL · 10b5-1 | 2026-09-04 | 2026-09-09 | $90.56 | $906K | -5.4% | -10.7% | — |
| TARS | SELL · 10b5-1 | 2026-09-02 | 2026-09-03 | $80.06 | $801K | -6.1% | -10.0% | — |
| TARS | SELL · 10b5-1 | 2026-06-17 | 2026-06-22 | $61.55 | $615K | +1.2% | -11.0% | +19.8% |
| TARS | SELL | 2026-03-17 | 2026-03-19 | $68.34 | $2.4M | +5.1% | -1.2% | -6.4% |
| TARS | SELL · 10b5-1 | 2025-12-24 | 2025-12-30 | $82.47 | $944K | -7.9% | -19.8% | -18.4% |
| TARS | SELL · 10b5-1 | 2025-09-24 | 2025-09-26 | $55.37 | $332K | +24.0% | +21.1% | +45.3% |
| TARS | SELL · 10b5-1 | 2025-08-11 | 2025-08-13 | $50.00 | $300K | +8.8% | -5.1% | +45.4% |
| TARS | SELL | 2025-03-24 | 2025-03-26 | $50.00 | $300K | -7.1% | -2.2% | -19.0% |
| TARS | SELL | 2025-03-18 | 2025-03-20 | $48.03 | $2.3M | -0.8% | -1.6% | -16.7% |
| TARS | SELL | 2024-03-18 | 2024-03-19 | $30.60 | $319K | +13.2% | +3.7% | -8.9% |
| TARS | SELL · 10b5-1 | 2023-12-27 | 2023-12-29 | $20.22 | $162K | +9.0% | +39.9% | +81.8% |
| TARS | SELL · 10b5-1 | 2023-12-20 | 2023-12-22 | $20.27 | $1.6M | -1.8% | +27.2% | +68.6% |
| TARS | SELL · 10b5-1 | 2023-11-15 | 2023-11-17 | $18.36 | $290K | -10.4% | +2.9% | +71.1% |
| TARS | SELL · 10b5-1 | 2023-10-18 | 2023-10-20 | $13.24 | $106K | +12.1% | +35.2% | +76.5% |
| TARS | SELL · 10b5-1 | 2023-09-20 | 2023-09-22 | $17.21 | $138K | +5.9% | -22.7% | +19.0% |
| TARS | SELL · 10b5-1 | 2023-08-23 | 2023-08-25 | $17.23 | $138K | -11.1% | -6.3% | -0.6% |
| TARS | SELL · 10b5-1 | 2023-07-19 | 2023-07-21 | $20.01 | $4.2M | -29.3% | -29.9% | -46.6% |
| TARS | SELL · 10b5-1 | 2023-07-12 | 2023-07-14 | $17.35 | $156K | +12.3% | -4.9% | -14.7% |
| TARS | SELL · 10b5-1 | 2023-06-21 | 2023-06-23 | $18.63 | $149K | -6.5% | +30.0% | -8.5% |
| TARS | SELL · 10b5-1 | 2023-06-14 | 2023-06-16 | $18.58 | $334K | -3.9% | +1.6% | -20.3% |
| TARS | SELL · 10b5-1 | 2023-06-08 | 2023-06-12 | $20.01 | $124K | +0.3% | -5.1% | -6.7% |
| TARS | SELL · 10b5-1 | 2023-05-17 | 2023-05-19 | $15.90 | $127K | +6.6% | +19.1% | +3.0% |
| TARS | SELL · 10b5-1 | 2023-05-10 | 2023-05-12 | $16.80 | $151K | -2.4% | +10.7% | +3.1% |
| TARS | SELL · 10b5-1 | 2023-04-28 | 2023-05-02 | $15.11 | $306K | +12.3% | +16.2% | +49.9% |
| TARS | SELL · 10b5-1 | 2023-04-21 | 2023-04-25 | $15.03 | $35K | +7.2% | +11.1% | +67.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.